The answer comes from a mediation analysis of the EMPA-REG OUTCOME Trial.

Higher score measuring severity of pain indicated elevated treatment failure risk.

Young patients with low BMIs, C-peptide levels, and significant symptoms at onset of diabetes at higher risk of undergoing rapid C-peptide decline.

Patients are not seeing the expected results because of medication adherence.

By Guest Writer David Kliff, Publisher, Diabetic Investor

As 2018 begins, my attention turns toward a look back at the year gone by and ahead to the year that’s starting. As always, my New Year will begin in that beautiful city by the bay at the JP Morgan Healthcare Conference. This is a conference I suspect will be one of the more interesting, and since I’ve attended nearly 20, that’s saying something. Lots is going on behind the scenes in our wacky world, and given the nature of JPM I suspect the veil of secrecy will be lifted.

Insulin Biosimilars for both long- and short-acting insulins will be available shortly from major insulin suppliers. Will you recommend them if they are at least 20% lower in cost? Follow the link to see what your colleagues say.

Download the PracticeUpdate app today for FREE, and enjoy all the quality information, expert commentary, and customized content you love in a mobile-friendly package. Expert-selected articles and research. Quit roaming from site to site, and rely on our industry experts to hand-select the top articles, studies, and breaking news from 100s of journals.

A 43-year-old patient presents to your clinic for an appointment. She has mild hypertension, which is currently well controlled with a beta blocker. She was diagnosed with type 2 diabetes 6 years ago, and has been taking metformin and glipizide. She has noticed that her recent self-blood glucose monitoring numbers have been creeping up with a most recent FPG of 160 mg/dl. At today’s visit, she has an A1C of 8.0%. She tells you that until now her job has required she travel several times a month. This week, she was promoted to a managerial position that does not require travel. Which of the following approaches would be the best for her? 1. Add a basal insulin dose once a day 2. Add pre-mixed insulin twice a day 3. Add pre-mixed insulin twice a day and change her non-insulin medications 4. Add a basal insulin dose once a day and change her non-insulin medications Follow the link for the answer.

Mary Loeken, Ph.D., received her Ph.D. in Reproductive Endocrinology at the University of Maryland School of Medicine and did postdoctoral training at the National Cancer Institute's Laboratory of Molecular Virology

In this interview transcript, Mary Loeken discusses her research into maternal diabetes, and how increased glucose metabolism, as a result of the mother’s glucose going to the embryo, causes abnormal expression of genes; as well as what pathways may be crucial in leading to malformations, and how there might eventually be strategies to prevent the malformations from occurring.